All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
TP53 inactivation can occur by different mechanisms, such as MDM2/MDMX upregulation and downstream effects of NPM1 and FLT3 mutations; therefore, the targeting of these pathways is being investigated in the clinical setting. Blocking the MDM2-TP53 interaction with inhibitors, such as idasanutlin, KRT-232, or APG-115, can prevent the proteasomal degradation of TP53 and reinstate apoptosis mechanisms.